Leucht, S, Pitschel-Walz, G, Abraham, D, Kissling, W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999; 35: 51–68.CrossRefGoogle ScholarPubMed

Geddes, J, Freemantle, N, Harrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000; 321: 1371–6.CrossRefGoogle ScholarPubMed

Glazer, WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry. 2000; 61 (Suppl 3): 16–21.Google ScholarPubMed

Hippius, H. The history of clozapine. Psychopharmacology. 1989; 99: S3-S5.CrossRefGoogle ScholarPubMed

Meltzer, H. Introduction. Psychopharmacology. 1989; 99: S1-S2.CrossRefGoogle Scholar

Meltzer, HY. What’s atypical about atypical antipsychotic drugs? Curr Opin Pharmacol. 2004; 4: 53–7.CrossRefGoogle ScholarPubMed

Meltzer, HY, Matsubara, S, Lee, J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989; 251: 238–46.Google ScholarPubMed

Burris, KD, Molski, TF, Xu, C, Ryan, E, Tottori, K, Kikuchi, T, Yocca, FD, Molinoff, PB. Aripiprazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002; 302: 381–9.CrossRefGoogle ScholarPubMed

Kapur, S, Remington, G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001; 50: 873–83.CrossRefGoogle ScholarPubMed

Westerink, BHC. Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur J Pharmacol. 2002; 455: 1–18.CrossRefGoogle ScholarPubMed

Kapur, S, Zipursky, RB, Remington, G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999; 156: 286–93.CrossRefGoogle ScholarPubMed

Caroff, SN, Mann, SC, Campbell, EC, Sullivan, KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry. 2002; 63 (Suppl 4): 12–9.Google ScholarPubMed

Hutton, P, Morrison, AP, Yung, AR, Taylor, PJ, French, P, Dunn, G. Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia. Acta Psychiatr Scand. 2012; 126: 1–11.CrossRefGoogle ScholarPubMed

Woods, SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003; 64: 663–7.CrossRefGoogle ScholarPubMed

Rijcken, CA, Monster, TB, Brouwers, JR, de Jong-van den Berg, LT. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses? J Clin Psychopharmacol. 2003; 23: 657–9.CrossRefGoogle ScholarPubMed

Lehman, AF, Lieberman, JA, Dixon, LB, et al. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161 (2 Suppl): 1–56.Google Scholar

Jeste, DV, Okamoto, A, Napolitano, J, Kane, JM, Martinez, RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000; 157: 1150–5.CrossRefGoogle ScholarPubMed

Dolder, CR, Jeste, DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry. 2003; 53: 1142–5.CrossRefGoogle ScholarPubMed

Grant, MJ, Baldessarini, RJ. Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother. 2005; 39: 1953.CrossRefGoogle ScholarPubMed

Kinon, BJ, Jeste, DV, Kollack-Walker, S, Stauffer, V, Liu-Seifert, H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28: 985–96.CrossRefGoogle ScholarPubMed

Miller, DD, Caroff, SN, Davis, SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Brit J Psychiat. 2008; 193: 279–88.CrossRefGoogle Scholar

Kane, JM, McGlashan, TH. Treatment of schizophrenia. Lancet. 1995; 346: 820–5.CrossRefGoogle ScholarPubMed

Hugenholtz, GW, Heerdink, ER, Stolker, JJ, Meijer, WE, Egberts, AC, Nolen, WA. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry. 2006; 67: 897–903.CrossRefGoogle ScholarPubMed

Simpson, GM, Lindenmayer, JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol. 1997; 17: 194–201.CrossRefGoogle ScholarPubMed

Castelao, JF, Ferreira, L, Gelders, YG, et al. The efficacy of the D2 and 5-HT2 antagonist risperidone (R64,766) in the treatment of chronic psychosis. An open dose-finding study. Schizophr Res. 1989; 2: 411–5.CrossRefGoogle Scholar

Peuskens, J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995; 166:712–33.CrossRefGoogle Scholar

Lemmens, P, Brecher, M, Van Baelen, B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extra pyramidal symptoms. Acta Psychiatr Scand. 1999; 99: 160–70.CrossRefGoogle Scholar

Kopala, LC, Good, KP, Honer, WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Psychopharmacol. 1997; 17: 308–13.Google ScholarPubMed

Rosebush, PI, Mazurek, MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology. 1999; 52: 782–5.CrossRefGoogle ScholarPubMed

Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373: 31–41.CrossRefGoogle ScholarPubMed

Tarsy, D, Lungu, C, Baldessarini, RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol. 2011; 100: 601–16.CrossRefGoogle ScholarPubMed

Correll, CU, Schenk, EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008; 21: 151–6.CrossRefGoogle ScholarPubMed

Correll, CU, Leucht, S, Kane, JM, Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004; 161: 414–25.CrossRefGoogle ScholarPubMed

Ye, M, Tang, W, Liu, L, et al. Prevalence of tardive dyskinesia in chronic male inpatients with schizophrenia on long-term clozapine versus typical antipsychotics. Int Clin Psychopharmacol. 2014 May 16 [Epub ahead of print].CrossRefGoogle Scholar

Bhidayasiri, R, Fahn, S, Weiner, WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013; 81: 463–9.CrossRefGoogle Scholar

Trollor, JN, Chen, X, Sachdev, PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009; 23: 477–92.CrossRefGoogle ScholarPubMed

Caroff, SN, Mann, SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993; 77: 185–202.CrossRefGoogle ScholarPubMed

Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45: 789–96.CrossRefGoogle ScholarPubMed

Essali, A, Al-Haj Haasan, N, Li, C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia (Review). Cochrane Database Syst Rev. 2009; 1: CD000059.Google Scholar

Asenjo Lobos, C, Komossa, K, Rummel-Kluge, C, Hunger, H, Schmid, F, Schwarz, S, Leucht, S. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010; 11: CD006633.Google Scholar

Diederich, NJ, Fénelon, G, Stebbins, G, Goetz, CG. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009; 5: 331–42.CrossRefGoogle ScholarPubMed

The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Eng J Med. 1999; 340: 757–63.Google Scholar

Factor, SA, Friedman, JH, Lannon, MC, Oakes, D, Bourgeois, K, and The Parkinson Study Group. Clozapine for the treatment of drug-induced psychosis in Parkinson’s disease: Results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord. 2001; 16: 135–9.3.0.CO;2-Q>CrossRefGoogle ScholarPubMed

Pollak, P, Tison, F, Rascol, O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004; 75: 689–95.CrossRefGoogle ScholarPubMed

Alvir, JMJ, Lieberman, JA, Safferman, AZ, Schwimmer, JL, Schaaf, JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med. 1993; 329: 162–7.CrossRefGoogle ScholarPubMed

Barak, Y, Wittenberg, N, Naor, S, Kutzuk, D, Weizman, A. Clozapine in elderly psychiatric patients: tolerability, safety, end efficacy. Compr Psychiatry. 1999; 40: 320–5.CrossRefGoogle Scholar

Snowdon, J, Halliday, G. A study of the use of clozapine in old age psychiatry. Int Clin Psychopharmacol. 2011; 26: 232–5.CrossRefGoogle ScholarPubMed

Suttajit, S, Srisurapanont, M, Xia, J, Suttajit, S, Maneeton, B, Maneeton, N. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev. 2013; 5: CD007815.Google Scholar

Asmal, L, Flegar, SJ, Wang, J, Rummel-Kluge, C, Komossa, K, Leucht, S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013; 11: CD006625.Google Scholar

Evatt, ML, Jewart, D, Juncos, JL. ‘Seroquel’ treatment of psychosis in parkinsonism. Mov Disord. 1996; 11: 595.Google Scholar

Friedman, JH, Factor, SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord. 2000; 15: 201–11.3.0.CO;2-D>CrossRefGoogle ScholarPubMed

Henderson, MJ, Mellers, JDC. Psychosis in Parkinson’s disease: `between a rock and a hard place’. Int Rev Psychiatry. 2000; 12: 319–34.CrossRefGoogle Scholar

Seppi, K, Weintraub, D, Coelho, M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011; 26 (Suppl 3): S42–80.CrossRefGoogle ScholarPubMed

Ondo, WG, Tintner, R, Voung, KD, Lai, D, Double-blind, Ringholz G., placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005; 20: 958–63.CrossRefGoogle ScholarPubMed

Rabey, JM, Prokhorov, T, Miniovitz, A, Dobronevsky, E, Klein, C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007; 22: 313–8.CrossRefGoogle ScholarPubMed

Shotbolt, P, Samuel, M, David, A. Quetiapine in the treatment of psychosis in Parkinson’s disease. Ther Adv Neurol Disord. 2010; 3: 339–50.CrossRefGoogle ScholarPubMed

Fernandez, HH, Friedman, JH, Jacques, C, Rosenfeld, M. Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord. 1999; 14: 484–7.3.0.CO;2-B>CrossRefGoogle ScholarPubMed

Morgante, L, Epifanio, A, Spina, E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004; 27: 153–6.CrossRefGoogle ScholarPubMed

Merims, D, Balas, M, Peretz, C, Shabtai, H, Rater-blinded, Giladi N., prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol. 2006; 29: 331–7.CrossRefGoogle ScholarPubMed

Simpson, GM, Lindenmayer, JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol. 1997; 17: 194–201.CrossRefGoogle ScholarPubMed

Castelão, JF, Ferreira, L, Gelders, YG, Heylen, SL. The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. An open dose-finding study. Schizophr Res. 1989; 2: 411–5.CrossRefGoogle Scholar

Marder, SR, Meibach, RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151: 825–35.Google ScholarPubMed

Claus, A, Bollen, J, De Cuyper, H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992; 85: 295–305.CrossRefGoogle ScholarPubMed

Min, SK, Rhee, CS, Kim, CE, Kang, DY. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J. 1993; 34: 179–90.CrossRefGoogle ScholarPubMed

Hunter, RH, Joy, CB, Kennedy, E, Gilbody, SM, Song, F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2003; 2: CD000440.Google Scholar

Gilbody, SM, Bagnall, AM, Duggan, L, Tuunainen, A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2000; 3: CD002306.Google Scholar

Ford, B, Lynch, T, Greene, P. Risperidone in Parkinson’s disease. Lancet. 1994; 344: 681.CrossRefGoogle ScholarPubMed

Rich, SS, Friedman, JH, Ott, BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry. 1995; 56: 556–9.Google ScholarPubMed

Goetz, CG, Blasucci, LM, Leurgans, S, Pappert, EJ. Olanzapine and clozapine. Comparative effects on motor function in hallucinating PD patients. Neurology. 2000; 55: 789–94.CrossRefGoogle ScholarPubMed

Duggan, L, Fenton, M, Rathbone, J, Dardennes, R, El-Dosoky, A, Indran, S. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2005; 2: CD001359.Google Scholar

Komossa, K, Rummel-Kluge, C, Hunger, H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010; 3: CD006654.Google Scholar

Breier, A, Sutton, VK, Feldman, PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry. 2002; 52: 438–45.CrossRefGoogle ScholarPubMed

Ondo, WG, Levy, JK, Vuong, KD, Hunter, C, Jankovic, J. Olanzapine treatment for dopaminergic induced hallucinations. Mov. Disord. 2002; 17: 1031–5.CrossRefGoogle ScholarPubMed

Bagnall, A, Lewis, RA, Leitner, ML, Kleijnen, J. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2000; 2: CD001945.Google Scholar

Komossa, K, Rummel-Kluge, C, Hunger, H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009; 4: CD006627.Google Scholar

Schindehütte, J, Trenkwalder, C. Treatment of drug-induced psychosis in Parkinson’s disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg. 2007; 109: 188–91.CrossRefGoogle ScholarPubMed

Pintor, L, Valldeoriola, F, Baillés, E, Martí, MJ, Muñiz, A, Tolosa, E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012; 35: 61–66.CrossRefGoogle ScholarPubMed

Bhattacharjee, J, El-Sayeh, HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2008; 3: CD006617.Google Scholar

Khanna, P, Suo, T, Komossa, K, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014; 1: CD006569.Google Scholar

Friedman, JH, Berman, RM, Goetz, CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov Disord. 2006; 21: 2078–81.CrossRefGoogle ScholarPubMed

Barbato, L, Monge, A, Stocchi, F, Nordera, G. Melperone in the treatment of iatrogenic psychosis in Parkinson’s disease. Funct Neurol. 1996; 11: 201–7.Google ScholarPubMed

Friedman, JH. Melperone is ineffective in treating Parkinson’s disease psychosis. Mov Disord. 2012; 27: 803–4.CrossRefGoogle ScholarPubMed

Wang, SM, Han, C, Lee, SJ, Patkar, AA, Masand, PS, Pae, CU. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol. 2013; 36: 223–38.CrossRefGoogle ScholarPubMed